Poison or cure: Meanings of medication in schizophrenia

Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry

Volumn 35, Issue 2, 2007, Pages 189-201

  Rosenfield, Paul J ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

AGRANULOCYTOSIS; AKATHISIA; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DOCTOR PATIENT RELATION; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; PARKINSONISM; PATIENT COMPLIANCE; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; COOPERATIVE BEHAVIOR; HUMANS; INDIVIDUALITY; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; PSYCHIATRY; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT REFUSAL;

EID: 34547409953     PISSN: 15460371     EISSN: None     Source Type: Journal    
DOI: 10.1521/jaap.2007.35.2.189     Document Type: Conference Paper

References (31)

1. Beasley, J.C.M., Tollefson, G., Tran, P., Satterlee, W., Sanger T., & Hamilton, S. (1996). Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
2. Byerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F., & Carmody, T. et al. (2005). A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research, 133, 129-133.
3. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27, 596-601.
4. Correll, C.U., Frederickson, A.M., Kane, J.M., & Manu, P. (2006). Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Journal of Clinical Psychiatry, 67, 575-583.
5. Correll, C.U., Leucht, S., & Kane, J.M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry, 161, 414-425.
6. Day, J.C., Bentall, R.P., Roberts, C., Randall, F., Rogers, A., & Cattell, D. et al. (2005). Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Archives of General Psychiatry, 62, 717-724.
7. Gilmer, T.P., Dolder, C.R., Lacro, J.P., Folsom, D.P., Lindamer, L., Garcia, P., & Jeste, D.V. (2004). Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. American Journal of Psychiatry, 161, 692-699.
8. Gitlin, M., Nuechterlein, K., Subotnik, K.L., Ventura, J., Mintz, J., & Fogelson, D.L. et al. (2001). Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry, 158, 1835-1842.
9. Green, M.F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
10. Healy, D. (2002). The creation of psychopharmacology. Cambridge, MA: Harvard University Press.
11. Lacro, J.P., Dunn, L.B., Dolder, C.R., Leckband, S.G.,&Jeste, D.V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892-909.
12. Lambert, M.T., Copeland, L.A., Sampson, N., &Duffy, S.A. (2006). New-onset type-2 diabetes associated with atypical antipsychotic medications. Progress in Neuropsychopharmacology & Biological Psychiatry, 30, 919-923.
13. Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003). New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet, 361, 1581-1589.
14. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., & Perkins, D.O. et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
15. Meyer, J.M. (2004). Treating the mind and body in schizophrenia: Risks and prevention. CNS Spectrum, 9, 25-33.
16. Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry, 63, 679-685.
17. Pear, R. (2006, January 21). Medicare woes take high toll on mentally ill. www.nytimes.com.
18. Perkins, D.O. (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63, 1121-1128.
19. Porter, R. (1988). A social history of madness: The world through the eyes of the insane (1st American ed.). New York: Weidenfeld & Nicolson.
20. Revicki, D.A. (2001). Cost effectiveness of the newer atypical antipsychotics: A review of the pharmacoeconomic research evidence. Current Opinions Investigation Drugs, 2, 110-117.
21. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., & Geisler, S. et al. (1999a). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241-247.
22. Robinson, D.G., Woerner, M.G., Alvir, J.M., Geisler, S., Koreen, A., & Sheitman, B. et al. (1999b). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156, 544-549.
23. Robinson, D.G., Woerner, M.G., McMeniman, M., Mendelowitz, A., & Bilder, R.M. (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 473-479.
24. Rogers, A., Day, J.C., Williams, B., Randall, F., Wood, P., Healy, D., & Bentall, R.P. (1998). The meaning and management of neuroleptic medication:Astudy of patients with a diagnosis of schizophrenia. Social Science & Medicine, 47, 1313-1323.
25. Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., & Warren, S. et al. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. Journal of the American Medical Association, 290, 2693-2702.
26. Rothman, D.J. (2003). Strangers at the bedside: A history of how law and bioethics transformed medical decision making (2nd pbk. ed.). New York: Aldine de Gruyter.
27. Schneider, L.S., Dagerman, K.S., & Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 1934-1943.
28. Scull, A.T. (2005). Madhouse: A tragic tale of megalomania and modern medicine. New Haven: Yale University Press.
29. Tollefson, G.D., Beasley, C.M., Jr., Tran, P.V., Street, J.S., Krueger, J.A., & Tamura, R.N. et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
30. Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.P., Citrome, L., & McEvoy, J.P. et al. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 159, 255-262.
31. Wagner, P.S., & Spiro, C.S. (2005, August 7). We Both Live Here. www.nytimes.com.